Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
2019 · The Lancet Neurology · 2,430 citations
https://doi.org/10.1016/s1474-4422(19)30320-5
T
Thomas Foltynie
University College London Hospitals NHS Foundation Trust(GB)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
549
Papers
37.0K
Citations
98
h-index
300
i10-index
Thomas Foltynie is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Parkinson's Disease Mechanisms and Treatments & Neurological disorders and treatments & Genetic Neurodegenerative Diseases. The author has an h-index of 98, co-authored 467 publications.
ORCID: 0000-0003-0752-1813Papers by this author
worksExenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
2017 · The Lancet · 811 citations
https://doi.org/10.1016/s0140-6736(17)31585-4
Exenatide and the treatment of patients with Parkinson’s disease
2013 · Journal of Clinical Investigation · 494 citations
https://doi.org/10.1172/jci68295
Progress towards therapies for disease modification in Parkinson's disease
2021 · The Lancet Neurology · 384 citations
https://doi.org/10.1016/s1474-4422(21)00061-2
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
2014 · Journal of Parkinson s Disease · 292 citations
https://doi.org/10.3233/jpd-140364
Connectivity derived thalamic segmentation in deep brain stimulation for tremor
2018 · NeuroImage Clinical · 196 citations
https://doi.org/10.1016/j.nicl.2018.01.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat